Benzinga | Jul 29, 2021 11:20AM EDT

Aegis Capital Initiates Coverage On Evogene with Buy Rating, Announces Price Target of $10

Aegis Capital analyst Nathan Weinstein initiates coverage on Evogene (NASDAQ:EVGN) with a Buy rating and announces Price Target of $10.